Verisante Aura Named Finalist for 2013 SPIE Prism Award
November 20 2012 - 01:40PM
Marketwired
Verisante Technology, Inc. (TSX
VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or
"Verisante"), a leader in cancer detection technology, announced
today that Verisante's Aura(TM), the revolutionary skin cancer
detection device, has been named a finalist for the 2013 Prism
Awards in the Life Sciences and Biophotonics category.
"We are honoured to be a finalist for this prestigious Award,"
said Thomas Braun, President and CEO. "It is very gratifying to be
recognized as an industry leader for our innovative and disruptive
technology, which has the potential to improve patient outcomes,
reduce wait times and also save the health care system time and
money. The Aura is a game changing technology because in half a
second it will tell doctors if a suspicious skin lesion is high or
low risk for being cancerous and should be biopsied or not."
Verisante will be in attendance when the winner will be
announced at the 2013 Prism Awards banquet on February 6 in San
Francisco. The Verisante Aura(TM) beta units are currently
installed at five leading dermatology clinics across Canada for
software verification purposes. This is the final step prior to
making this device available in Canada, 27 European countries, and
Australia where the device has already been approved for sale. The
Verisante Aura(TM) is expected to be commercially available in
Canada, Europe and Australia in early 2013.
About the 2013 Prism Awards
The Prism Awards, named the "Photonics Oscar" by OptecNet
Deutschland, is a celebration of the best of our industry. It takes
place every year in conjunction with SPIE Photonics West in San
Francisco, California.
The Prism Awards for Photonics Innovation is a leading
international competition that honors the best new photonic
products on the market. Over the years, the Prism Awards has
received applications from more than 35 countries across the globe.
Applications are judged by panel of leading industry experts,
venture capitalists, luminaries and visionaries. The finalists and
winners that are ultimately chosen (from General Electric, Agilent,
Hamamatsu to Swamp Optics, Optotune, WiTec) reflect the diversity
of the program.
SPIE Photonics West is the world's largest and most influential
photonics and optics event with over 1500 companies exhibiting and
20,000 attendees.
To find out more about the Awards, visit the website at
http://www.photonicsprismaward.com.
About Verisante Technology, Inc.
Verisante is a medical device company committed to
commercializing innovative systems for the early detection of
cancer. The Verisante Aura(TM) for skin cancer detection and the
Verisante Core(TM) series for lung, colon and cervical cancer
detection utilize a proprietary cancer detection platform while the
operating software and probe technology are unique to each device.
The cancer detection platform was developed by the BC Cancer Agency
and tested and refined at the Skin Care Centre at Vancouver General
Hospital. This exclusive platform technology allows Verisante to
develop and offer a range of compact, non-invasive cancer detection
devices that offer physicians immediate results for many of the
most common cancers. The Aura(TM) has been approved for sale in
Canada, Europe and Australia. The Core(TM) has not yet been
approved for sale.
Verisante Aura(TM) was awarded Popular Science Magazine's "Best
of What's New Award" for 2011, and Verisante Core(TM) was named one
of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer
Society. In addition, the Company was named a finalist for the 2011
Regional Awards for New Technology by the Canadian Manufacturers
& Exporters and the National Research Council of Canada and
named as the year's top ranking Technology and Life Sciences
Company on the TSX Venture 50.
Forward Looking Statements
This release contains forward-looking statements, including, but
not limited to, statements regarding the future commercialization
of medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks,
and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These
statements are made based upon current expectations and actual
results may differ from those projected due to a number of risks
and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of
the contents of this press release. Neither the TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this press
release.
Contacts: Verisante Technology, Inc. Thomas Braun President
& CEO (604) 605-0507info@verisante.com www.verisante.com
Youtube: www.youtube.com/verisante Twitter:
www.twitter.com/verisante Facebook: www.facebook.com/verisante